echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The world's first nasopharyngeal cancer immunotherapy drug-Tuoyi New Indications National Launch Conference held

    The world's first nasopharyngeal cancer immunotherapy drug-Tuoyi New Indications National Launch Conference held

    • Last Update: 2021-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com




    Professor Xu Ruihua,





    Among 92 patients with relapsed/metastatic nasopharyngeal carcinoma who had failed at least second-line chemotherapy in the POLARIS-02 study, the objective response rate (ORR) of teriprizumab monotherapy was 23.


    In addition, in the field of first-line treatment, the JUPITER-02 study, which also has Professor Ruihua Xu as the main investigator, has also reached the main research endpoint


    Professor Mai Haiqiang said, “Treplimumab, as a drug produced by an innovative Chinese pharmaceutical company, leads the international treatment plan and defines a new treatment method for nasopharyngeal cancer through global multi-center clinical research, which is the first-line immunotherapy for nasopharyngeal cancer.


    Dr.


    Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.